JP2021054765A - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- JP2021054765A JP2021054765A JP2019180604A JP2019180604A JP2021054765A JP 2021054765 A JP2021054765 A JP 2021054765A JP 2019180604 A JP2019180604 A JP 2019180604A JP 2019180604 A JP2019180604 A JP 2019180604A JP 2021054765 A JP2021054765 A JP 2021054765A
- Authority
- JP
- Japan
- Prior art keywords
- component
- oral composition
- acetate
- mass
- limonene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- -1 acetate ester compound Chemical class 0.000 claims abstract description 38
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 30
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000001510 limonene Nutrition 0.000 claims abstract description 15
- 229940087305 limonene Drugs 0.000 claims abstract description 15
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims abstract description 13
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims abstract description 13
- 229930007744 linalool Natural products 0.000 claims abstract description 13
- 239000003205 fragrance Substances 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 12
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 12
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 12
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 10
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 claims description 10
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 claims description 10
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 9
- 229940041616 menthol Drugs 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetate Chemical compound CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 claims description 6
- 229940022663 acetate Drugs 0.000 claims description 5
- 229940007550 benzyl acetate Drugs 0.000 claims description 5
- YDZCHDQXPLJVBG-UHFFFAOYSA-N hex-1-enyl acetate Chemical compound CCCCC=COC(C)=O YDZCHDQXPLJVBG-UHFFFAOYSA-N 0.000 claims description 5
- 229940117955 isoamyl acetate Drugs 0.000 claims description 5
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 claims description 4
- NFLGAXVYCFJBMK-IUCAKERBSA-N (-)-isomenthone Chemical compound CC(C)[C@@H]1CC[C@H](C)CC1=O NFLGAXVYCFJBMK-IUCAKERBSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- HIGQPQRQIQDZMP-UHFFFAOYSA-N geranil acetate Natural products CC(C)=CCCC(C)=CCOC(C)=O HIGQPQRQIQDZMP-UHFFFAOYSA-N 0.000 claims description 4
- HIGQPQRQIQDZMP-DHZHZOJOSA-N geranyl acetate Chemical compound CC(C)=CCC\C(C)=C\COC(C)=O HIGQPQRQIQDZMP-DHZHZOJOSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 4
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 4
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 4
- 229930007503 menthone Natural products 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000002040 relaxant effect Effects 0.000 abstract description 16
- 239000008368 mint flavor Substances 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 description 18
- 210000000214 mouth Anatomy 0.000 description 18
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000001953 sensory effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000002324 mouth wash Substances 0.000 description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 6
- 229940051866 mouthwash Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002542 deteriorative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229910001631 strontium chloride Inorganic materials 0.000 description 3
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 1
- HKKXJKUATKEWDT-UHFFFAOYSA-N 2-ethyl-2-(tetradecylamino)butanoic acid Chemical compound C(CCCCCCCCCCCCC)NC(C(=O)O)(CC)CC HKKXJKUATKEWDT-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- NOOLISFMXDJSKH-LPEHRKFASA-N Isomenthol Natural products CC(C)[C@@H]1CC[C@H](C)C[C@H]1O NOOLISFMXDJSKH-LPEHRKFASA-N 0.000 description 1
- 102100037644 Kelch-like protein 41 Human genes 0.000 description 1
- 108050003242 Kelch-like protein 41 Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- 241000333569 Pyrola minor Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XHXUANMFYXWVNG-WCQGTBRESA-N [(1s,2r,5s)-5-methyl-2-propan-2-ylcyclohexyl] acetate Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(C)=O XHXUANMFYXWVNG-WCQGTBRESA-N 0.000 description 1
- GWVPJQDUGPKIOI-UQKRIMTDSA-N [Na].CCCCCCCCCCCC(=O)CN[C@@H](C)C(O)=O Chemical compound [Na].CCCCCCCCCCCC(=O)CN[C@@H](C)C(O)=O GWVPJQDUGPKIOI-UQKRIMTDSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940070818 glycyrrhizate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- NPKKRSHVJIQBKU-UHFFFAOYSA-N ornogenin Natural products CC(OC(=O)C=Cc1ccccc1)C2(O)CCC3(O)C4(O)CC=C5CC(O)CCC5(C)C4CC(OC(=O)C=Cc6ccccc6)C23C NPKKRSHVJIQBKU-UHFFFAOYSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- SLBXZQMMERXQAL-UHFFFAOYSA-M sodium;1-dodecoxy-4-hydroxy-1,4-dioxobutane-2-sulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O SLBXZQMMERXQAL-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229940013553 strontium chloride Drugs 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Abstract
Description
本発明は、口の中のすっきり感を与えつつ、リラックス効果を有する口腔用組成物に関する。 The present invention relates to an oral composition having a relaxing effect while giving a refreshing feeling in the mouth.
特許文献1は、口腔用組成物について記載している。ミント系の香料であるメントールを0.1〜1.0質量%、リナロールを0.001〜0.4質量%含有している。 Patent Document 1 describes an oral composition. It contains 0.1 to 1.0% by mass of menthol, which is a mint-based fragrance, and 0.001 to 0.4% by mass of linalool.
特許文献1の口腔用組成物では、ミント系の香料であるメントールを相対的に多く含有しているため、口の中のすっきり感が得られるものの、メントールが有する覚醒効果によって就寝前など鎮静が望まれる状態での使用には適さない場合があるという課題を有している。 Since the oral composition of Patent Document 1 contains a relatively large amount of menthol, which is a mint-based fragrance, a refreshing feeling in the mouth can be obtained, but the awakening effect of menthol provides sedation before going to bed. It has a problem that it may not be suitable for use in a desired state.
本発明は、こうした実情に鑑みてなされたものであり、その目的は、口の中のすっきり感を与えつつ、リラックス効果を有する口腔用組成物を提供することにある。 The present invention has been made in view of such circumstances, and an object of the present invention is to provide an oral composition having a relaxing effect while giving a refreshing feeling in the mouth.
上記課題を解決するための口腔用組成物は、A成分:ミント系の香料と、B成分:リモネン、及び、リナロールから選ばれる少なくとも一種と、C成分:酢酸エステル化合物とを含有してなる口腔用組成物であって、前記A成分を0.01〜0.6質量%、前記B成分のうち、前記リモネンを0.01質量%以上、及び/又は、前記リナロールを0.001質量%以上、前記C成分を0.001質量%以上含有する。 An oral composition for solving the above problems is an oral composition containing A component: a mint-based fragrance, B component: limonene, at least one selected from linalool, and C component: an acetate ester compound. In the composition for use, the A component is 0.01 to 0.6% by mass, the limonene is 0.01% by mass or more, and / or the linalool is 0.001% by mass or more among the B components. , The C component is contained in an amount of 0.001% by mass or more.
上記口腔用組成物について、前記ミント系の香料が、メントール、メントン、及び、イソメントンから選ばれる少なくとも二種以上であることが好ましい。
上記口腔用組成物について、前記酢酸エステル化合物が、酢酸エチル、酢酸ブチル、酢酸イソブチル、酢酸イソアミル、酢酸ヘキシル、酢酸ヘキセニル、酢酸ベンジル、酢酸リナリル、酢酸ゲラニルから選ばれる少なくとも一種であることが好ましい。
With respect to the oral composition, it is preferable that the mint-based fragrance is at least two or more selected from menthol, menthone, and isomenthone.
For the oral composition, the acetic acid ester compound is preferably at least one selected from ethyl acetate, butyl acetate, isobutyl acetate, isoamyl acetate, hexyl acetate, hexenyl acetate, benzyl acetate, linaryl acetate and geranyl acetate.
上記口腔用組成物について、前記B成分として前記リモネンを含有することが好ましい。
上記口腔用組成物について、液状に構成されていることが好ましい。
The oral composition preferably contains the limonene as the B component.
The oral composition is preferably composed in a liquid state.
本発明の口腔用組成物によれば、口の中のすっきり感を与えつつ、リラックス効果を得ることができる。 According to the oral composition of the present invention, a relaxing effect can be obtained while giving a refreshing feeling in the mouth.
以下、本発明の口腔用組成物を具体化した一実施形態について説明する。
本実施形態の口腔用組成物は、A成分:ミント系の香料と、B成分:リモネン、及び、リナロールから選ばれる少なくとも一種と、C成分:酢酸エステル化合物とを含有している。
Hereinafter, an embodiment in which the oral composition of the present invention is embodied will be described.
The oral composition of the present embodiment contains a component A: a mint-based fragrance, a component B: limonene, and at least one selected from linalool, and a component C: an acetic acid ester compound.
A成分であるミント系の香料としては、特に限定されず、ミント系の天然香料や合成香料を用いることができる。ミント系の香料の成分の具体例としては、例えば、メントール、メントン、イソメントン、シオネール、プレゴン、メンチルアセテート等を挙げることができる。その中でも、メントール、メントン、イソメントンから選ばれる少なくとも二種以上を含有することが好ましい。 The mint-based fragrance as the component A is not particularly limited, and mint-based natural fragrances and synthetic fragrances can be used. Specific examples of the components of the mint-based fragrance include menthol, menthol, isomenthol, eucalyptol, pulegone, mentholacetate and the like. Among them, it is preferable to contain at least two kinds selected from menthol, menthone and isomenthone.
A成分は、口腔用組成物中に0.01〜0.6質量%含有されている。A成分は、口腔用組成物中に0.01〜0.1質量%含有されていることが好ましく、0.01〜0.06質量%含有されていることがより好ましい。A成分の含有量をかかる範囲に規定することにより、口の中のすっきり感が得られる。なお、口腔用組成物中の各成分の含有量は、水等の溶媒を含めた口腔用組成物中の含有量を示す。また、本明細書において、数値範囲を「〜」を用いて表す場合、その両端の数値を含むものとする。 The component A is contained in the oral composition in an amount of 0.01 to 0.6% by mass. The component A is preferably contained in the oral composition in an amount of 0.01 to 0.1% by mass, more preferably 0.01 to 0.06% by mass. By defining the content of component A in such a range, a refreshing feeling in the mouth can be obtained. The content of each component in the oral composition indicates the content in the oral composition including a solvent such as water. Further, in the present specification, when the numerical range is represented by using "~", the numerical values at both ends thereof are included.
B成分としてリモネンを含有する場合、口腔用組成物中に0.01質量%以上含有されている。リモネンは、口腔組成物中に0.01〜0.1質量%含有されていることが好ましく、0.01〜0.05質量%含有されていることがより好ましい。 When limonene is contained as the B component, it is contained in an oral composition in an amount of 0.01% by mass or more. Limonene is preferably contained in the oral composition in an amount of 0.01 to 0.1% by mass, more preferably 0.01 to 0.05% by mass.
B成分としてリナロールを含有する場合、口腔用組成物中に0.001質量%以上含有されている。リナロールは、口腔組成物中に0.001〜0.05質量%含有されていることが好ましく、0.001〜0.005質量%含有されていることがより好ましい。 When linalool is contained as the B component, it is contained in an oral composition in an amount of 0.001% by mass or more. Linalool is preferably contained in the oral composition in an amount of 0.001 to 0.05% by mass, more preferably 0.001 to 0.005% by mass.
B成分の含有量をかかる範囲に規定することにより、口の中のすっきり感及び香味の嗜好性を低下させることなく、リラックス効果が得られる。
C成分である酢酸エステル化合物の具体例としては、特に限定されず、例えば、酢酸エチル、酢酸ブチル、酢酸イソブチル、酢酸イソアミル、酢酸ヘキシル、酢酸ヘキセニル、酢酸ベンジル、酢酸リナリル、酢酸ゲラニル等を挙げることができる。その中でも、酢酸ヘキセニル、酢酸イソアミル、酢酸リナリル、酢酸ベンジルから選ばれる少なくとも一種を含有することが好ましい。
By defining the content of the B component in such a range, a relaxing effect can be obtained without deteriorating the refreshing feeling in the mouth and the palatability of the flavor.
Specific examples of the acetic acid ester compound as the C component are not particularly limited, and examples thereof include ethyl acetate, butyl acetate, isobutyl acetate, isoamyl acetate, hexyl acetate, hexenyl acetate, benzyl acetate, linaryl acetate, and geranyl acetate. Can be done. Among them, it is preferable to contain at least one selected from hexenyl acetate, isoamyl acetate, linalyl acetate and benzyl acetate.
C成分は、口腔用組成物中に0.001質量%以上含有されている。C成分は、口腔用組成物中に0.001〜0.01質量%含有されていることが好ましく、0.001〜0.005質量%含有されていることがより好ましい。 The C component is contained in the oral composition in an amount of 0.001% by mass or more. The component C is preferably contained in the oral composition in an amount of 0.001 to 0.01% by mass, more preferably 0.001 to 0.005% by mass.
C成分の含有量をかかる範囲に規定することにより、口の中のすっきり感及び香味の嗜好性を低下させることなく、リラックス効果が得られる。
口腔用組成物の適用形態は、特に限定されず、例えば医薬品、医薬部外品、化粧品として使用することができる。口腔用組成物の用途としては、公知のものを適宜採用することができ、例えば練歯磨剤、洗口剤、含漱剤、液体歯磨剤、バイオフィルム分散剤、口臭予防剤、歯茎マッサージ剤、口腔用湿潤付与剤、舌苔除去剤、口腔内塗布剤、口腔殺菌剤、咽喉殺菌剤、口腔咽喉剤、歯周病治療剤、義歯装着剤、義歯コーティング剤、義歯安定化剤、義歯保存剤、義歯洗浄剤、インプラントケア剤等が挙げられる。
By defining the content of the C component in such a range, a relaxing effect can be obtained without deteriorating the refreshing feeling in the mouth and the palatability of the flavor.
The application form of the oral composition is not particularly limited, and can be used as, for example, pharmaceuticals, quasi-drugs, and cosmetics. As the use of the oral composition, known ones can be appropriately adopted, for example, denture polish, mouthwash, rinsing agent, liquid toothpaste, biofilm dispersant, mouth odor preventive agent, gum massage agent, etc. Oral moisturizer, tongue moss remover, oral coating agent, oral sterilizer, throat sterilizer, oropharyngeal agent, periodontal disease treatment agent, denture wearing agent, denture coating agent, denture stabilizer, denture preservative, Examples include denture cleaning agents and implant care agents.
口腔用組成物の剤形は、特に限定されず、例えば水、アルコール等の溶媒を含有することにより、軟膏剤、ペースト剤、パスタ剤、スプレー剤、ジェル剤、液剤、懸濁・乳化剤、ガム剤等に適用することができる。 The dosage form of the oral composition is not particularly limited, and for example, by containing a solvent such as water or alcohol, an ointment, a paste, a pasta, a spray, a gel, a liquid, a suspension / emulsifier, or a gum It can be applied to agents and the like.
溶媒として用いられる水の種類は特に限定されず、例えば蒸留水、純水、超純水、精製水、水道水等を用いることができる。溶媒として用いられるアルコールの種類は特に限定されず、例えばエタノールを用いることができる。水とアルコールを混合して用いることもできる。 The type of water used as the solvent is not particularly limited, and for example, distilled water, pure water, ultrapure water, purified water, tap water, or the like can be used. The type of alcohol used as the solvent is not particularly limited, and for example, ethanol can be used. Water and alcohol can be mixed and used.
口腔用組成物が液状に構成されている場合において、水等の溶媒の含有量は、60〜99.8質量%であることが好ましく、70〜90質量%であることがより好ましい。
口腔用組成物は、適用目的、形態、用途等に応じて、前述した成分以外の成分、例えば抗菌剤、抗炎症剤、香料、湿潤剤、界面活性剤、研磨剤、アルコール類、増粘剤、甘味成分、薬用成分、着色剤、安定化剤、pH調整剤等を配合してもよい。これら各成分は、口腔用組成物に配合される公知のものを使用することができる。これらの成分は、それぞれ1種のみを適用してもよく、2種以上を組み合わせて適用してもよい。
When the oral composition is composed of a liquid, the content of the solvent such as water is preferably 60 to 99.8% by mass, more preferably 70 to 90% by mass.
The oral composition has components other than the above-mentioned components, such as antibacterial agents, anti-inflammatory agents, fragrances, wetting agents, surfactants, abrasives, alcohols, and thickeners, depending on the purpose of application, form, application, and the like. , Sweetness component, medicinal component, colorant, stabilizer, pH adjuster and the like may be blended. As each of these components, known ones to be blended in the oral composition can be used. Only one type of each of these components may be applied, or two or more types may be applied in combination.
抗菌剤の具体例としては、例えば塩化セチルピリジニウム、パラベン、安息香酸ナトリウム、トリクロサン、塩酸クロルヘキシジン、イソプロピルメチルフェノール、塩化ベンザルコニウム、塩化ベンゼトニウム、ヒノキチオール等が挙げられる。 Specific examples of the antibacterial agent include cetylpyridinium chloride, paraben, sodium benzoate, triclosan, chlorhexidine hydrochloride, isopropylmethylphenol, benzalkonium chloride, benzethonium chloride, hinokithiol and the like.
抗炎症剤の具体例としては、例えばグリチルリチン酸塩、トラネキサム酸、ε−アミノカプロン酸、オウバクエキス等が挙げられる。
香料の具体例としては、例えばアネトール、オイゲノール、カルボン、ウインターグリーン、サリチル酸メチル、チモール、丁字油、セージ油、オシメン油、シトロネロール等が挙げられる。
Specific examples of the anti-inflammatory agent include glycyrrhizate, tranexamic acid, ε-aminocaproic acid, Phellodendron amur extract and the like.
Specific examples of the fragrance include anethole, eugenol, carboxylic, winter green, methyl salicylate, thymol, clove oil, sage oil, osimene oil, citronellol and the like.
湿潤剤の具体例としては、例えばソルビット、グリセリン、エチレングリコール、プロピレングリコール、1,3−ブチレングリコール、ポリエチレングリコール等の多価アルコール等が挙げられる。 Specific examples of the wetting agent include polyhydric alcohols such as sorbitol, glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, and polyethylene glycol.
界面活性剤の具体例としては、例えば非イオン性界面活性剤、アニオン界面活性剤、両性界面活性剤が挙げられる。
非イオン性界面活性剤の具体例としては、例えばショ糖脂肪酸エステル、マルトース脂肪酸エステル等の糖脂肪酸エステル、マルチトール脂肪酸エステル等の糖アルコール脂肪酸エステル、モノラウリン酸ソルビタン等のソルビタン脂肪酸エステル、ポリオキシエチレンソルビタンモノラウレート、ポリオキシエチレンソルビタンモノステアレート等のポリオキシエチレンソルビタン脂肪酸エステル、ラウリン酸ジエタノールアミド等の脂肪酸アルカノールアミド、ポリオキシエチレンステアリルエーテル、ポリオキシエチレンオレイルエーテル等のポリオキシエチレンアルキルエーテル、モノオレイン酸ポリエチレングリコール、モノラウリン酸ポリエチレングリコール等のポリエチレングリコール脂肪酸エステル、ラウリルグルコシド、デシルグルコシド等のアルキルグルコシド、ポリグリセリン脂肪酸エステル、ポリオキシエチレングリセリン脂肪酸エステル、ポリオキシエチレン脂肪酸エステル、アルキルグルコシド類、ポリオキシエチレン硬化ヒマシ油、グリセリン脂肪酸エステル、ポリオキシエチレンプロピレンブロックコポリマー等が挙げられる。
Specific examples of the surfactant include nonionic surfactants, anionic surfactants, and amphoteric surfactants.
Specific examples of the nonionic surfactant include sugar fatty acid esters such as sucrose fatty acid ester and maltose fatty acid ester, sugar alcohol fatty acid esters such as multitoll fatty acid ester, sorbitan fatty acid ester such as sorbitan monolaurate, and polyoxyethylene. Polyoxyethylene sorbitan fatty acid esters such as sorbitan monolaurate and polyoxyethylene sorbitan monostearate, fatty acid alkanolamides such as laurate diethanolamide, polyoxyethylene alkyl ethers such as polyoxyethylene stearyl ether and polyoxyethylene oleyl ether, Polyethylene glycol fatty acid esters such as polyethylene glycol monooleate and polyethylene glycol monolaurate, alkyl glucosides such as lauryl glucoside and decyl glucoside, polyglycerin fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyoxyethylene fatty acid esters, alkyl glucosides, poly Examples thereof include oxyethylene hydrogenated castor oil, glycerin fatty acid ester, and polyoxyethylene propylene block copolymer.
アニオン界面活性剤の具体例としては、例えばラウリル硫酸ナトリウム、ポリオキシエチレンラウリルエーテル硫酸ナトリウム等の硫酸エステル塩、ラウリルスルホコハク酸ナトリウム、ポリオキシエチレンラウリルエーテルスルホコハク酸ナトリウム等のスルホコハク酸塩、ココイルサルコシンナトリウム、ラウロイルメチルアラニンナトリウム等のアシルアミノ酸塩、ココイルメチルタウリンナトリウム等が挙げられる。 Specific examples of the anionic surfactant include sulfate esters such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate, sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate, and sodium cocoyl sarcosin. , Acrylic amino acid salts such as sodium lauroylmethylalanine, sodium cocoylmethyltaurine and the like.
両性界面活性剤の具体例としては、例えばNーラウリルジアミノエチルグリシン、Nーミリスチルジエチルグリシン等のアミノ酸型両性界面活性剤、アルキルジメチルアミノ酢酸ベタイン、N−アルキル−N’−カルボキシメチル−N’−ヒドロキシエチルエチレンジアミン塩、及び2−アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリニウムベタイン等のベタイン系両性界面活性剤等が挙げられる。 Specific examples of amphoteric tensides include amino acid amphoteric tensides such as N-lauryldiaminoethylglycine and N-myristyldiethylglycine, alkyldimethylaminoacetate betaine, and N-alkyl-N'-carboxymethyl-N'. Examples thereof include −hydroxyethylethylenediamine salt and betaine amphoteric surfactants such as 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine.
研磨剤の具体例としては、例えば炭酸カルシウム、炭酸マグネシウム、第二リン酸カルシウム、第三リン酸カルシウム、リン酸マグネシウム、シリカ、ゼオライト、メタリン酸ナトリウム、水酸化アルミニウム、水酸化マグネシウム、ピロリン酸カルシウム、ベンガラ、硫酸カルシウム、無水ケイ酸等が挙げられる。 Specific examples of the abrasive include calcium carbonate, magnesium carbonate, calcium dibasic phosphate, calcium tribasic phosphate, magnesium phosphate, silica, zeolite, sodium metaphosphate, aluminum hydroxide, magnesium hydroxide, calcium pyrophosphate, red iron oxide, calcium sulfate. , Calcium anhydride and the like.
アルコール類の具体例としては、例えばエチルアルコール、ラウリルアルコール、ミリスチルアルコール等が挙げられる。
増粘剤の具体例としては、例えばポリアクリル酸ナトリウム、カラギーナン、カルボキシメチルセルロースナトリウム、アルギン酸ナトリウム、キサンタンガム、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、アルギン酸プロピレングリコールエステル等が挙げられる。
Specific examples of alcohols include ethyl alcohol, lauryl alcohol, myristyl alcohol and the like.
Specific examples of the thickener include sodium polyacrylate, carrageenan, sodium carboxymethyl cellulose, sodium alginate, xanthan gum, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, propylene glycol alginate and the like.
甘味成分の具体例としては、例えばサッカリン、サッカリンナトリウム、スクラロース、ステビオサイド、アセスルファムカリウム、アスパルテーム、キシリトール、マルチトール、エリスリトール、シクロヘプタアミロース等が挙げられる。 Specific examples of the sweetening component include saccharin, sodium saccharin, sucralose, stebioside, acesulfame potassium, aspartame, xylitol, maltitol, erythritol, cycloheptaamylose and the like.
薬用成分の具体例としては、例えばモノフルオロリン酸ナトリウム、フッ化ナトリウム、フッ化第1スズ、フッ化ストロンチウム等のフッ化物、ピロリン酸ナトリウムやポリリン酸ナトリウム等の縮合リン酸塩、リン酸一水素ナトリウム、リン酸三ナトリウム等のリン酸塩、アスコルビン酸、アスコルビン酸ナトリウム、塩酸ピリドキシン、トコフェロール酢酸エステル等のビタミン剤、デキストラナーゼ、ムタナーゼ等のグルカナーゼ酵素、プロテアーゼ、リゾチーム等の分解酵素、塩化亜鉛、クエン酸亜鉛、塩化ストロンチウム、硝酸カリウム等の無機塩類、クロロフィル、グリセロホスフェート等のキレート性化合物、脂を溶解するポリエチレングリコール等、塩化ナトリウム、乳酸アルミニウム、塩化ストロンチウム等が挙げられる。 Specific examples of medicinal ingredients include fluorides such as sodium monofluorophosphate, sodium fluoride, stannous fluoride and strontium chloride, condensed phosphates such as sodium pyrophosphate and sodium polyphosphate, and monophosphate. Phosphates such as sodium hydrogen hydrogen and trisodium phosphate, vitamins such as ascorbic acid, sodium ascorbate, pyridoxin hydrochloride, tocopherol acetate, glucanase enzymes such as dextranase and mutanase, degrading enzymes such as protease and lysoteam, chloride Examples thereof include inorganic salts such as zinc, zinc citrate, strontium chloride and potassium nitrate, chelating compounds such as chlorophyll and glycerophosphate, polyethylene glycol which dissolves fat, sodium chloride, aluminum lactate and strontium chloride.
着色剤の具体例としては、例えば緑色1号、青色1号、黄色4号等の法定色素、酸化チタン等が挙げられる。
安定化剤の具体例としては、例えばエデト酸ナトリウム、チオ硫酸ナトリウム、亜硫酸ナトリウム、乳酸カルシウム、ラノリン、トリアセチン、ヒマシ油、硫酸マグネシウム等が挙げられる。
Specific examples of the colorant include legal dyes such as Green No. 1, Blue No. 1, and Yellow No. 4, titanium oxide, and the like.
Specific examples of the stabilizer include sodium edetate, sodium thiosulfate, sodium sulfite, calcium lactate, lanolin, triacetin, castor oil, magnesium sulfate and the like.
pH調整剤の具体例としては、例えばクエン酸、リンゴ酸、乳酸、酒石酸、酢酸、リン酸、ピロリン酸、グリセロリン酸、並びにこれらのカリウム塩、ナトリウム塩及びアンモニウム塩等の各種塩、水酸化ナトリウム等が挙げられる。口腔用組成物は、pH調整剤を配合することにより、pHが4〜9、特に5〜7の範囲になるように調整されていることが好ましい。 Specific examples of the pH adjuster include citric acid, malic acid, lactic acid, tartaric acid, acetic acid, phosphoric acid, pyrophosphate, glycerophosphate, various salts such as potassium salt, sodium salt and ammonium salt thereof, and sodium hydroxide. And so on. The oral composition is preferably adjusted so that the pH is in the range of 4 to 9, particularly 5 to 7, by blending a pH adjusting agent.
本実施形態の口腔用組成物の効果について説明する。
(1)本実施形態の口腔用組成物は、A成分:ミント系の香料と、B成分:リモネン、及び、リナロールから選ばれる少なくとも一種と、C成分:酢酸エステル化合物とを含有している。A成分を0.01〜0.6質量%、B成分のうち、リモネンを0.01質量%以上、及び/又は、リナロールを0.001質量%以上、C成分を0.001質量%以上含有する。A成分を上記数値範囲含有することにより、口の中のすっきり感を与えることができる。また、B成分とC成分を上記数値範囲含有することにより、口の中のすっきり感及び香味の嗜好性を低下させることなく、リラックス効果を得ることができる。したがって、就寝前など鎮静が望まれる状態での使用にも適した口腔用組成物を得ることができる。
The effect of the oral composition of the present embodiment will be described.
(1) The oral composition of the present embodiment contains A component: a mint-based fragrance, B component: limonene, at least one selected from linalool, and C component: an acetic acid ester compound. A component is 0.01 to 0.6% by mass, limonene is 0.01% by mass or more, and / or linalool is 0.001% by mass or more, and C component is 0.001% by mass or more. To do. By containing the component A in the above numerical range, a refreshing feeling in the mouth can be given. Further, by containing the B component and the C component in the above numerical range, a relaxing effect can be obtained without deteriorating the refreshing feeling in the mouth and the palatability of the flavor. Therefore, it is possible to obtain an oral composition suitable for use in a state where sedation is desired, such as before going to bed.
(2)ミント系の香料が、メントール、メントン、及び、イソメントンから選ばれる少なくとも二種以上である。したがって、A成分による口の中のすっきり感がより好適なものとなる。 (2) At least two or more mint-based fragrances are selected from menthol, menthone, and isomenthon. Therefore, the refreshing feeling in the mouth due to the component A becomes more preferable.
(3)酢酸エステル化合物が、酢酸エチル、酢酸ブチル、酢酸イソブチル、酢酸イソアミル、酢酸ヘキシル、酢酸ヘキセニル、酢酸ベンジル、酢酸リナリル、酢酸ゲラニルから選ばれる少なくとも一種である。したがって、C成分によるリラックス効果がより好適なものとなる。 (3) The acetic acid ester compound is at least one selected from ethyl acetate, butyl acetate, isobutyl acetate, isoamyl acetate, hexyl acetate, hexenyl acetate, benzyl acetate, linaryl acetate and geranyl acetate. Therefore, the relaxing effect of the C component becomes more preferable.
(4)B成分としてリモネンを含有する。したがって、B成分によるリラックス効果がより好適なものとなる。
(5)口腔用組成物は、液状に構成されている。したがって、口腔用組成物が固体状に構成された態様に比べて、口腔内に適用してからより短時間で効果を得ることができる。
(4) Contains limonene as component B. Therefore, the relaxing effect of the B component becomes more preferable.
(5) The oral composition is composed of a liquid. Therefore, the effect can be obtained in a shorter time after the oral composition is applied into the oral cavity, as compared with the embodiment in which the oral composition is formed in a solid state.
本実施形態は、以下のように変更して実施することができる。本実施形態及び以下の変更例は、技術的に矛盾しない範囲で互いに組み合わせて実施することができる。
・上記実施形態において上述したA成分、B成分、及びC成分は、使用時に口腔用組成物中に配合されていればよく、保存時においては複数剤に分けて保存してもよい。また、口腔用組成物を粉末等の固体状の剤として保存し、使用時に水等の溶媒を加えて液状に構成してもよい。かかる構成においても、口の中のすっきり感を与えつつ、リラックス効果を得ることができる。
This embodiment can be modified and implemented as follows. The present embodiment and the following modified examples can be implemented in combination with each other within a technically consistent range.
-In the above embodiment, the above-mentioned A component, B component, and C component may be blended in the oral composition at the time of use, and may be divided into a plurality of agents at the time of storage. Further, the oral composition may be stored as a solid agent such as powder, and may be made liquid by adding a solvent such as water at the time of use. Even in such a configuration, a relaxing effect can be obtained while giving a refreshing feeling in the mouth.
本発明の口腔用組成物について、以下の試験例に基づいてさらに詳細に説明する。なお、本発明は、実施例欄記載の構成に限定されるものではない。
表1に示す実施例1、2、及び、比較例1、2の口腔用組成物を常法に従って各成分を混合、撹拌することによって製造した。口腔用組成物のその他成分における香料には、A成分、B成分、及びC成分がほとんど含まれないものを用いた。ここで、「ほとんど含まれないもの」には、全く含有していないものだけでなく、不純物レベル程度含有するものが含まれるものとする。製造された口腔用組成物は液状であった。表1において、各成分の右側に記載した数値は、口腔用組成物における含有量(質量%)を意味する。
The oral composition of the present invention will be described in more detail based on the following test examples. The present invention is not limited to the configuration described in the Example column.
The oral compositions of Examples 1 and 2 and Comparative Examples 1 and 2 shown in Table 1 were produced by mixing and stirring each component according to a conventional method. As the fragrance in the other components of the oral composition, those containing almost no A component, B component, and C component were used. Here, it is assumed that "things that are hardly contained" include not only those that are not contained at all but also those that are contained at an impurity level. The oral composition produced was liquid. In Table 1, the numerical value shown on the right side of each component means the content (mass%) in the oral composition.
(評価試験)
実施例1、2、及び、比較例1、2の口腔用組成物について、口の中のすっきり感、及び、香味の嗜好性についての官能評価を行った。また、リラックス効果について、皮膚電気反応(以下、「GSR」ともいう。)を測定した。GSRは、皮膚において観測される電位的活動と発汗に伴うインピーダンス変動の総称を意味する。緊張、ストレス、不安などの心理的動揺により、交感神経が活発になると、抹消での発汗が起こる。GSRはこのような精神性発汗を反映しやすい指先や掌に電極を装着し、測定を行うことで、末梢部自律神経系の交感神経の指標として用いられる。
(Evaluation test)
The oral compositions of Examples 1 and 2 and Comparative Examples 1 and 2 were subjected to a sensory evaluation of the refreshing feeling in the mouth and the taste of flavor. In addition, the skin electrical reaction (hereinafter, also referred to as "GSR") was measured for the relaxing effect. GSR is a general term for the potential activity observed in the skin and the impedance fluctuation associated with sweating. When the sympathetic nerve becomes active due to psychological agitation such as tension, stress, and anxiety, sweating occurs in the peripheral. GSR is used as an index of the sympathetic nerve of the peripheral autonomic nervous system by attaching electrodes to the fingertips and palms that easily reflect such mental sweating and measuring them.
(すっきり感についての官能評価)
すっきり感についての官能評価は、10人のモニターにより行った。各実施例、各比較例で調製した口腔用組成物を洗口液として10ml口に含み、20秒間洗口を行った。洗口液を吐き出した後、口の中のすっきり感について視覚的評価スケール(以下、「VAS」ともいう。)を用いて以下の評価基準で評価した。
(Sensory evaluation of refreshing feeling)
The sensory evaluation of the feeling of cleanliness was performed by 10 monitors. The oral composition prepared in each Example and each Comparative Example was contained in a 10 ml mouthwash as a mouthwash, and the mouth was washed for 20 seconds. After the mouthwash was spit out, the feeling of cleanliness in the mouth was evaluated using the following evaluation criteria using a visual evaluation scale (hereinafter, also referred to as "VAS").
(評価基準)
直線の左端を「全く感じない」、直線の右端を「非常に感じる」とし、感じた強度に応じて任意の位置に印をつけることで評価した。直線の左端を0点、直線の右端を100点とし、直線の左端側からの距離により評点を算出した。10人のモニターによる官能評価の値を集計して平均値を算出した。以下のように、平均値が60点以上で良好な結果が得られているとした。結果を表1に示す。
(Evaluation criteria)
The left end of the straight line was "not felt at all" and the right end of the straight line was "very felt", and the evaluation was made by marking arbitrary positions according to the felt intensity. The left end of the straight line was set to 0 points, the right end of the straight line was set to 100 points, and the score was calculated from the distance from the left end side of the straight line. The values of sensory evaluation by 10 monitors were totaled to calculate the average value. As shown below, it was assumed that good results were obtained when the average value was 60 points or more. The results are shown in Table 1.
◎:80点以上
○:60点以上、80点未満
△:40点以上、60点未満
×:40点未満
(香味の嗜好性についての官能評価)
香味の嗜好性についての官能評価は、上記すっきり感についての官能評価と同様に行い、すっきり感の官能評価と同時に行った。香味の嗜好性についてVASを用いて以下の評価基準で評価した。
⊚: 80 points or more ○: 60 points or more and less than 80 points Δ: 40 points or more and less than 60 points ×: less than 40 points (sensory evaluation of flavor preference)
The sensory evaluation of the taste of flavor was performed in the same manner as the sensory evaluation of the refreshing feeling, and was performed at the same time as the sensory evaluation of the refreshing feeling. The taste of flavor was evaluated using VAS according to the following evaluation criteria.
(評価基準)
直線の左端を「嫌い」、直線の右端を「好き」とし、好みに応じて任意の位置に印をつけることで評価した。直線の左端を0点、直線の右端を100点とし、直線の左端側からの距離により評点を算出した。10人のモニターによる官能評価の値を集計して平均値を算出した。以下のように、平均値が60点以上で良好な結果が得られているとした。結果を表1に示す。
(Evaluation criteria)
The left end of the straight line was "disliked" and the right end of the straight line was "liked". The left end of the straight line was set to 0 points, the right end of the straight line was set to 100 points, and the score was calculated from the distance from the left end side of the straight line. The values of sensory evaluation by 10 monitors were totaled to calculate the average value. As shown below, it was assumed that good results were obtained when the average value was 60 points or more. The results are shown in Table 1.
◎:80点以上
○:60点以上、80点未満
△:40点以上、60点未満
×:40点未満
(リラックス効果)
リラックス効果は、10人のモニターのGSRを測定して行った。
⊚: 80 points or more ○: 60 points or more and less than 80 points △: 40 points or more and less than 60 points ×: less than 40 points (relaxing effect)
The relaxing effect was measured by measuring the GSR of 10 monitors.
GSRの測定手順について以下に説明する。
まず、10人のモニターが、安静期として10分間安静にした後、ストレス課題としてクレペリン検査を20分間連続的に行った。その後、調製した洗口液としての口腔用組成物を10ml口に含み、20秒間洗口を行った。洗口液を吐き出した後、回復期として20分間安静にした。安静期、ストレス課題時、回復期を通じて、モニターに装着したGSRの計測センサーによってGSRを測定した。10人のモニターが各実施例、各比較例の洗口液を使用して、上記GSRの測定手順に従ってGSRの測定を繰り返し行った。
The GSR measurement procedure will be described below.
First, 10 monitors rested for 10 minutes as a resting period, and then a Kleperin test was continuously performed for 20 minutes as a stress task. Then, 10 ml of the prepared oral composition as a mouthwash was contained in the mouth, and the mouth was washed for 20 seconds. After spitting out the mouthwash, the patient was rested for 20 minutes as a recovery period. The GSR was measured by the GSR measurement sensor attached to the monitor throughout the rest period, stress task, and recovery period. The GSR measurement was repeatedly performed by 10 monitors using the mouthwashes of each Example and each Comparative Example according to the above-mentioned GSR measurement procedure.
リラックス効果の評価には、GSRの測定値を標準化したZ値を用いた。Z値は、Z=(X−μ)/σより算出した。ここで、Xは標本データ、μはXの平均、σは標準偏差を意味する。Z値は、ストレス課題時に上昇し、その後徐々に低下する。ストレス課題終了時を基準として、課題終了後10分間のZ値の変化量の絶対値を測定した。10人の平均値を算出し、以下のように、平均値が1.0以上で良好な結果が得られているとした。結果を表1に示す。 For the evaluation of the relaxing effect, the Z value obtained by standardizing the measured value of GSR was used. The Z value was calculated from Z = (X−μ) / σ. Here, X means sample data, μ means the average of X, and σ means the standard deviation. The Z value increases during the stress task and then gradually decreases. The absolute value of the amount of change in the Z value for 10 minutes after the end of the stress task was measured with reference to the end of the stress task. The average value of 10 people was calculated, and it was assumed that good results were obtained when the average value was 1.0 or more as follows. The results are shown in Table 1.
(評価基準)
◎:1.2以上
○:1.0以上、1.2未満
△:0.8以上、1.0未満
×:0.8未満
(Evaluation criteria)
⊚: 1.2 or more ○: 1.0 or more and less than 1.2 Δ: 0.8 or more and less than 1.0 ×: less than 0.8
Claims (5)
B成分:リモネン、及び、リナロールから選ばれる少なくとも一種と、
C成分:酢酸エステル化合物とを含有してなる口腔用組成物であって、
前記A成分を0.01〜0.6質量%、
前記B成分のうち、前記リモネンを0.01質量%以上、及び/又は、前記リナロールを0.001質量%以上、
前記C成分を0.001質量%以上含有することを特徴とする口腔用組成物。 Ingredient A: Mint-based fragrance and
Ingredient B: At least one selected from limonene and linalool,
C component: An oral composition containing an acetic acid ester compound.
The A component is 0.01 to 0.6% by mass,
Among the B components, 0.01% by mass or more of the limonene and / or 0.001% by mass or more of the linalool.
An oral composition comprising 0.001% by mass or more of the C component.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019180604A JP7403736B2 (en) | 2019-09-30 | 2019-09-30 | Oral composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019180604A JP7403736B2 (en) | 2019-09-30 | 2019-09-30 | Oral composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021054765A true JP2021054765A (en) | 2021-04-08 |
JP7403736B2 JP7403736B2 (en) | 2023-12-25 |
Family
ID=75269787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019180604A Active JP7403736B2 (en) | 2019-09-30 | 2019-09-30 | Oral composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7403736B2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003212741A (en) | 2000-11-29 | 2003-07-30 | Lion Corp | Dentifrice composition |
AU2006302337C1 (en) | 2005-10-05 | 2013-04-04 | Intercontinental Great Brands Llc | Menthyl ester containing cooling compositions |
US20080102157A1 (en) | 2006-10-25 | 2008-05-01 | Steffen Hofacker | Flavored chewable foams and a process for their production |
JP2018104377A (en) | 2016-12-27 | 2018-07-05 | サンスター株式会社 | Composition for oral cavity |
-
2019
- 2019-09-30 JP JP2019180604A patent/JP7403736B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP7403736B2 (en) | 2023-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5684454B2 (en) | Oral care therapeutic and prophylactic compositions | |
KR100874301B1 (en) | Oral Composition | |
JP2007084471A (en) | Composition for oral cavity and method of selecting product for oral cavity | |
JP2019116510A (en) | Oral composition | |
US20120288451A1 (en) | Means for removing tobacco tars and composition containing same | |
JP5233399B2 (en) | Oral spray composition and oral preparation | |
JP2022000420A (en) | Oral cavity composition | |
JP2011105651A (en) | Spray composition and formulation for oral cavity | |
JP5397204B2 (en) | Oral composition | |
JP2013035792A (en) | Composition for oral cavity | |
WO2022131147A1 (en) | Oral cavity composition | |
JP2018104377A (en) | Composition for oral cavity | |
JP4452601B2 (en) | Liquid oral composition | |
JP2007197393A (en) | Dentifrice | |
JP4147412B2 (en) | Oral composition | |
JP2020083787A (en) | Composition for oral cavity | |
JP4656293B2 (en) | Oral composition | |
JP7403736B2 (en) | Oral composition | |
JP2022001553A (en) | Oral composition | |
JP7172028B2 (en) | oral composition | |
KR100704585B1 (en) | Toothpaste composition | |
JP6734090B2 (en) | Oral composition | |
CN110691581B (en) | Dentifrice composition | |
CN111031999B (en) | Toothpaste composition | |
KR102642592B1 (en) | Oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191029 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220916 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230925 |
|
TRDD | Decision of grant or rejection written | ||
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20231020 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231020 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7403736 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |